CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Status:
Terminated
Trial end date:
2015-12-15
Target enrollment:
Participant gender:
Summary
Background:
The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for
treating patients metastatic cancer that involves taking white blood cells from the patient,
growing them in the laboratory in large numbers, genetically modifying these specific cells
with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells
back to the patient. This type of therapy is called gene transfer. In this protocol, we are
modifying the patient s white blood cells with a retrovirus that has the gene for
anti-vascular endothelial growth factor receptor (VEGFR2) incorporated in the retrovirus.
Objectives:
- To determine a safe number of these cells to infuse and to see the safety and effectiveness
of cell therapy using anti-VEGFR2 gene modified tumor white blood cells to treat recurrent or
relapsed cancer.
Eligibility:
- Individuals greater than or equal to 18 years of age and less than or equal to 70 years of
age who have been diagnosed with metastatic cancer that has not responded to or has relapsed
after standard treatment.
Design:
- Work up stage: Patients will be seen as an outpatient at the National Institutes of
Health (NIH) clinical Center and undergo a history and physical examination, scans,
x-rays, lab tests, and other tests as needed
- Leukapheresis: If the patients meet all of the requirements for the study they will
undergo leukapheresis to obtain white blood cells to make the anti-VEGFR2 cells.
{Leukapheresis is a common procedure which removes only the white blood cells from the
patient.}
- Treatment: Once their cells have grown the patients will be admitted to the hospital for
the conditioning chemotherapy, the anti-VEGFR2 cells and aldesleukin. They will stay in
the hospital for about4 weeks for the treatment.
- Follow up: Patients will return to the clinic for a physical exam, review of side
effects, lab tests, and scans about every 1-3 months for the first year, and then every
6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up
to 2 days.